

General information about positive NIPT results: Trisomy 15

My patient's NIPT is positive for trisomy 15. What does this mean?

Your patient's noninvasive prenatal testing (NIPT) result suggests the presence of an extra copy of chromosome 15. NIPT is a screening test; false positives can occur. The actual chance for the pregnancy to have trisomy 15 depends on many factors, including the patient's clinical and family history.

Next steps to consider: You should discuss the results and the potential clinical implications with your patient. Globally, professional medical societies recommend that all women with a positive screening result should have genetic counseling and a comprehensive ultrasound evaluation with an opportunity for diagnostic testing to confirm the results.^{1,2} Confirmation prior to birth can also help with pregnancy and neonatal management.

See below for more information about trisomy 15.

What is trisomy 15?

Trisomy 15 is a condition that is caused by an extra chromosome number 15 (three copies instead of two).

What are the features of trisomy 15?

Most pregnancies with trisomy 15 will miscarry spontaneously. If a developing fetus has mosaic trisomy 15 (where some cells are normal and some cells have trisomy 15), there is an increased chance for the pregnancy to progress and possibly survive to term. However, liveborn infants with full or mosaic trisomy 15 are expected to have serious medical problems. Full trisomy 15 has been reported in association with multiple congenital anomalies and neonatal death. Mosaic trisomy 15 can be associated with growth restriction, intellectual disability (sometimes mild), and birth defects. In reported cases of prenatally diagnosed trisomy 15, the outcomes have ranged from normal to live births with clinical sequelae. The variability in clinical presentation is believed to be due to confined placental mosaicism (CPM; when trisomic cells are present in the placenta, but not in the fetus) or the degree of fetal mosaicism.

What is the prevalence of this condition?

Unknown, but rare. For this reason, positive predictive value (PPV) cannot be accurately calculated.

What testing could be considered?

Specialized genetic tests such as karyotyping, fluorescence *in situ* hybridization (FISH), quantitative polymerase chain reaction (qPCR), and microarray are available to confirm the presence of trisomy 15. Uniparental disomy (UPD) analysis is performed by specialized testing, such as single nucleotide polymorphism (SNP) microarray, methylation testing, and short tandem repeat (STR) marker testing.

These confirmatory tests are generally performed on cells from chorionic villus sampling (CVS) or amniocentesis during pregnancy, on cord blood or peripheral blood sample after the baby is born, or on

products of conception (POC) in the case of a miscarriage. The type of invasive procedure and diagnostic testing should take into account the underlying chromosome anomaly.^{3,4}

Ultrasound evaluation may be useful in aiding with a prenatal diagnosis of trisomy 15, but a normal ultrasound cannot exclude this condition.

Special considerations

Chromosome 15 is an imprinted chromosome and UPD for chromosome 15 has specific consequences. Maternal UPD 15 is associated with Prader-Willi syndrome. Paternal UPD 15 is associated with Angelman syndrome. There may be an increased risk for certain recessive conditions if UPD is present.

The American College of Medical Genetics and Genomics (ACMG) states that specialized UPD testing should be considered for patients when there is discordance noted between NIPT results and the diagnostic testing.⁵

Resources for trisomy 15

MedlinePlus Genetics
medlineplus.gov/genetics/chromosome/15

Unique, The Rare Chromosome Disorder Support Group
rarechromo.org

References

- Rose NC, Kaimal AJ, Dugoff L, et al. Screening for Fetal Chromosomal Abnormalities: ACOG Practice Bulletin, Number 226. *Obstet Gynecol.* 2020;136(4):e48-e69.
- Benn P, Borrell A, Chiu RW, et al. Position statement from the Chromosome Abnormality Screening Committee on behalf of the Board of the International Society for Prenatal Diagnosis. *Prenat Diagn.* 2015;35(8):725-734.
- Cherry AM, Akkari YM, Barr KM, et al. Diagnostic cytogenetic testing following positive noninvasive prenatal screening results: a clinical laboratory practice resource of the American College of Medical Genetics and Genomics (ACMG). *Genet Med.* 2017;19(8):845-850.
- Van Opstal D, Srebniak MI. Cytogenetic confirmation of a positive NIPT result: evidence-based choice between chorionic villus sampling and amniocentesis depending on chromosome aberration. *Expert Rev Mol Diagn.* 2016;16(5):513-520.
- Del Gaudio D, Shinawi M, Astbury C, et al. Diagnostic testing for uniparental disomy: a points to consider statement from the American College of Medical Genetics and Genomics (ACMG). *Genet Med.* 2020;22(7):1133-1141.

Additional resources

Chen CP, Chern SR, Chen YN, et al. Mosaic trisomy 15 at amniocentesis: Prenatal diagnosis, molecular genetic analysis and literature review. *Taiwan J Obstet Gynecol.* 2015;54(4):426-431.

Dighe M, Cheng E, Dubinsky T. Ultrasound manifestations of unusual trisomies-excluding trisomy 13, 18, and 21: a literature review. *Ultrasound Q.* 2009;25(1):15-24.

Trisomy 15 CPM: probable origins, pregnancy outcome and risk of fetal UPD: European Collaborative Research on Mosaicism in CVS (EUCROMIC). *Prenat Diagn.* 1999;19(1):29-35.

Gardner RJM, Amor DJ. *Gardner and Sutherland's Chromosome Abnormalities and Genetic Counseling*. 5th ed. Oxford University Press; 2018.

Hsu LY, Yu MT, Neu RL, et al. Rare trisomy mosaicism diagnosed in amniocytes, involving an autosome other than chromosomes 13, 18, 20, and 21: karyotype/phenotype correlations. *Prenat Diagn.* 1997;17(3):201-242.

Kotzot D. Prenatal testing for uniparental disomy: indications and clinical relevance. *Ultrasound Obstet Gynecol.* 2008;31(1):100-105.

Malvestiti F, Agrati C, Grimi B, et al. Interpreting mosaicism in chorionic villi: results of a monocentric series of 1001 mosaics in chorionic villi with follow-up amniocentesis. *Prenat Diagn*. 2015;35(11):1117-1127.

McPadden J, Helm BM, Spangler BB, Ross LP, Boles DB, Schrier Vergano SA. Mosaic trisomy 15 in a liveborn infant. *Am J Med Genet A*. 2015;167A(4):821-825.

Olander E, Stamberg J, Steinberg L, Wulfsberg EA. Third Prader-Willi syndrome phenotype due to maternal uniparental disomy 15 with mosaic trisomy 15. *Am J Med Genet*. 2000;93(3):215-218.

Philipp T, Terry J, Feichtinger M, Grillenberger S, Hartmann B, Jirecek S. Morphology of early intrauterine deaths with full trisomy 15. *Prenat Diagn*. 2018;38(4):267-272.

Zaslav AL, Fallet S, Brown S, et al. Prenatal diagnosis of low level trisomy 15 mosaicism: review of the literature. *Clin Genet*. 1998;53(4):286-292.

This content is intended for healthcare professional audiences only. The information provided in this sheet is based on a literature search updated in November 2020. This Information Sheet is intended to provide some general overview of the key issues relating to its subject matter. This sheet is not intended to be an exhaustive discussion of the subject covered by the sheet nor should it be used to substitute for the exercise of a Clinical Laboratory or a Healthcare Provider's legal or professional duties relative to interpreting the test results to which this Information Sheet relates. This sheet is also not intended to serve as a recommendation of management. This sheet is not intended to be a substitute for genetic counseling.
Pub. No. 1576-2020-050 QB9694